zafirlukast Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
leukotriene receptor antagonists 2855 107753-78-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ICI-204219
  • ICI 204219
  • ICI 204,219
  • zafirlukast
  • vanticon
a leukotriene D4 receptor antagonist
  • Molecular weight: 575.68
  • Formula: C31H33N3O6S
  • CLOGP: 7.09
  • LIPINSKI: 2
  • HAC: 9
  • HDO: 2
  • TPSA: 115.73
  • ALOGS: -5.78
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.99 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Sept. 26, 1996 FDA PAR PHARM INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 64.36 20.15 43 1953 91499 46592567
Dyspnoea 20.49 20.15 58 1938 515490 46168576
Bronchospasm 20.46 20.15 11 1985 15696 46668370

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 84.01 31.77 29 483 36145 29915821
Eosinophilic granulomatosis with polyangiitis 39.08 31.77 8 504 1307 29950659

Pharmacologic Action:

SourceCodeDescription
ATC R03DC01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Leukotriene receptor antagonists
FDA MoA N0000000083 Leukotriene Receptor Antagonists
FDA EPC N0000175777 Leukotriene Receptor Antagonist
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D006727 Hormone Antagonists
MeSH PA D020024 Leukotriene Antagonists
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:49159 ltra
CHEBI has role CHEBI:65023 antiasthmatic agent
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Asthma indication 195967001 DOID:2841
Asthma management indication 406162001
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Mood swings contraindication 18963009
Cirrhosis of liver contraindication 19943007 DOID:5082
Feeling agitated contraindication 24199005
Depressive disorder contraindication 35489007
Anxiety contraindication 48694002
Dream disorder contraindication 85418005
Liver function tests abnormal contraindication 166603001
Insomnia contraindication 193462001
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Nervousness contraindication
Tremors contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.84 acidic
pKa2 10.83 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cysteinyl leukotriene receptor 1 GPCR ANTAGONIST Ki 9.50 CHEMBL CHEMBL
Cytochrome P450 2C9 Enzyme IC50 5.65 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.24 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 5.42 DRUG MATRIX
Mitogen-activated protein kinase 3 Kinase IC50 5.36 DRUG MATRIX
Mitogen-activated protein kinase 14 Kinase IC50 6.45 DRUG MATRIX
Mitogen-activated protein kinase 1 Kinase IC50 6.27 DRUG MATRIX
Cytochrome P450 3A4 Enzyme Ki 4.87 WOMBAT-PK
Leukotriene B4 receptor 1 GPCR Ki 5.15 PDSP
Cysteinyl leukotriene receptor 2 GPCR ANTAGONIST IC50 5.15 IUPHAR
Solute carrier family 22 member 2 Transporter IC50 5.01 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 5.12 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.89 CHEMBL
Adenosine receptor A3 GPCR Ki 6.11 DRUG MATRIX
Cytosolic phospholipase A2 Enzyme IC50 4.07 CHEMBL
Cysteinyl leukotriene receptor 1 GPCR Ki 9.52 CHEMBL

External reference:

IDSource
4020987 VUID
N0000148457 NUI
D00411 KEGG_DRUG
4020987 VANDF
C0526503 UMLSCUI
CHEBI:10100 CHEBI
ZLK PDB_CHEM_ID
CHEMBL603 ChEMBL_ID
C062735 MESH_SUPPLEMENTAL_RECORD_UI
7244 INN_ID
XZ629S5L50 UNII
5717 PUBCHEM_CID
3322 IUPHAR_LIGAND_ID
DB00549 DRUGBANK_ID
114970 RXNORM
178409 MMSL
5701 MMSL
d04053 MMSL
006206 NDDF
108614003 SNOMEDCT_US
386880006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 0904-6646 TABLET, COATED 20 mg ORAL NDA 21 sections
Zafirlukast Human Prescription Drug Label 1 31722-007 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Zafirlukast Human Prescription Drug Label 1 31722-008 TABLET, FILM COATED 20 mg ORAL ANDA 19 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 49884-549 TABLET, COATED 10 mg ORAL NDA 21 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 49884-554 TABLET, COATED 20 mg ORAL NDA 21 sections
Accolate HUMAN PRESCRIPTION DRUG LABEL 1 49884-589 TABLET, COATED 10 mg ORAL NDA 23 sections
Accolate HUMAN PRESCRIPTION DRUG LABEL 1 49884-590 TABLET, COATED 20 mg ORAL NDA 23 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 50268-805 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
ACCOLATE HUMAN PRESCRIPTION DRUG LABEL 1 53808-0203 TABLET, FILM COATED 20 mg ORAL NDA 22 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 55111-625 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 55111-626 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 63629-2102 TABLET, COATED 10 mg ORAL NDA 21 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 68084-059 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Zafirlukast HUMAN PRESCRIPTION DRUG LABEL 1 68151-1977 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections